Published in Mayo Clin Proc on April 01, 2012
Daptomycin in Treating Neutropenia and Fever in Patients With Cancer | NCT00335478
A Study of Ceftobiprole in Patients With Fever and Neutropenia. | NCT00529282
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis (2016) 2.08
Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis. PLoS One (2012) 0.91
The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infections. PLoS One (2013) 0.83
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst (1959) 94.48
Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med (2005) 23.85
Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet (1998) 19.31
Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 11.12
Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis (2005) 9.23
Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis (2012) 7.97
High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med (2006) 7.56
Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm (2009) 7.43
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol (2004) 6.65
Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis (2004) 4.09
Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis (2002) 3.80
The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis (2007) 3.52
Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis (2011) 3.20
Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother (2008) 3.09
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis (2008) 2.73
Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother (2005) 2.66
Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis (2009) 2.54
Vancomycin: a history. Clin Infect Dis (2006) 2.52
Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis (2010) 2.41
Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis (2001) 2.19
A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis (2008) 2.15
Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother (1990) 2.06
Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis (2005) 1.95
Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest (2008) 1.87
Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother (2006) 1.84
A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract (2008) 1.76
Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother (2007) 1.68
Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis (2006) 1.67
CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother (2010) 1.67
Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother (2007) 1.60
CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother (2010) 1.58
A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer. J Infect Dis (1994) 1.50
Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis (2007) 1.49
Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients. Cochrane Database Syst Rev (2005) 1.48
Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother (2009) 1.47
Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon. Antimicrob Agents Chemother (1991) 1.41
From conference abstract to full paper: differences between data presented in conferences and journals. FASEB J (2005) 1.39
Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother (2005) 1.38
Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther (2003) 1.33
Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother (2008) 1.29
Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis (2005) 1.25
Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Int J Infect Dis (2005) 1.22
Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect (2006) 1.20
Trends in antimicrobial utilization at a tertiary teaching hospital during a 15-year period (1978-1992). Infect Control Hosp Epidemiol (1993) 1.06
Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother (2007) 1.05
Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother (2008) 1.03
Linezolid for the treatment of infections caused by Gram-positive pathogens in China. Int J Antimicrob Agents (2008) 1.01
Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis (2008) 1.01
Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents (2005) 1.01
Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med (2000) 1.00
Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents (2009) 1.00
Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother (2006) 0.97
Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents (2007) 0.96
Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters. Antimicrob Agents Chemother (1989) 0.95
Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy (2006) 0.95
Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts. Antimicrob Agents Chemother (1991) 0.95
Pulmonary disposition of vancomycin in critically ill patients. Eur J Clin Microbiol Infect Dis (1997) 0.93
Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. Medicine (Baltimore) (2009) 0.92
Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program. Antimicrob Agents Chemother (1994) 0.91
Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity. Antimicrob Agents Chemother (1991) 0.90
Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect Dis (2005) 0.90
Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother (2008) 0.90
Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results. J Antimicrob Chemother (1988) 0.89
Benefit-risk assessment of linezolid for serious gram-positive bacterial infections. Drug Saf (2008) 0.89
Linezolid: effectiveness and safety for approved and off-label indications. Expert Opin Pharmacother (2007) 0.86
Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surg Infect (Larchmt) (2003) 0.86
Association of pharmacokinetic and pharmacodynamic aspects of linezolid with infection outcome. Curr Drug Metab (2009) 0.84
The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. Int J Clin Pract (2009) 0.84
Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J (2003) 0.84
Comparative Study of Teicoplanin vs Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteraemia. Clin Drug Investig (1996) 0.83
New antibiotics for healthcare-associated pneumonia. Semin Respir Crit Care Med (2009) 0.81
Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia. Eur Respir J (2007) 0.80
Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. Eur J Clin Microbiol Infect Dis (1999) 0.80
Teicoplanin vs. vancomycin for the treatment of serious infections: a randomised trial. Int J Antimicrob Agents (1995) 0.78
[Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes]. Rev Clin Esp (1996) 0.78
Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for gram-positive infections in intensive care patients. Intensive Care Med (1994) 0.78
Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients. Oncol Rep (1998) 0.78
Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients. Haematologica (1999) 0.78
Comparison of efficacy and safety of teicoplanin and vancomycin in children with antineoplastic therapy-associated febrile neutropenia and gram-positive bacteremia. J Chemother (2000) 0.78
[The comparative costs of vancomycin treatment versus teicoplanin in osteoarticular infection caused by methicillin-resistant staphylococci]. Pathol Biol (Paris) (2001) 0.78
A prospective study comparing vancomycin and teicoplanin as second-line empiric therapy for infection in neutropenic patients. Br J Haematol (1990) 0.78
Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to gram-positive cocci in neutropenic patients with hematological malignancies: microbiological, clinical and economic evaluation. Chemotherapy (2004) 0.77
Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model. J Hosp Infect (2001) 0.77
Prospective, double-blind, randomized trial of teicoplanin versus vancomycin for the therapy of vascular access-associated bacteremia caused by gram-positive pathogens. J Infect Chemother (1999) 0.77
Systematic reviews and meta-analyses in infectious diseases: how are they done and what are their strengths and limitations? Infect Dis Clin North Am (2009) 0.76
Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections. Antimicrob Agents Chemother (2009) 0.76
Decreasing the incidence and impact of infections in neutropenic patients: evidence from meta-analyses of randomized controlled trials. Curr Med Res Opin (2008) 0.76
A bibliometric analysis of global research production in respiratory medicine. Chest (2005) 4.15
Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J (2008) 3.60
Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials. Crit Care Med (2010) 3.43
Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol (2009) 3.27
Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis (2008) 2.87
Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. J Antimicrob Chemother (2007) 2.79
Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med (2007) 2.58
Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother (2005) 2.47
Comparison of amount of biomedical research originating from the European Union and the United States. BMJ (2005) 2.42
Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol (2007) 2.35
Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis (2014) 2.29
Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg (2008) 2.10
β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis (2011) 2.03
Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother (2012) 2.01
Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother (2008) 1.98
Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis (2008) 1.91
Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis (2005) 1.89
Estimates of global production in cardiovascular diseases research. Int J Cardiol (2005) 1.87
Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug? J Infect (2012) 1.84
Epidemiology of constipation in Europe and Oceania: a systematic review. BMC Gastroenterol (2008) 1.77
Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials. PLoS Negl Trop Dis (2008) 1.75
Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis (2005) 1.74
Unique author identification number in scientific databases: a suggestion. PLoS Med (2006) 1.73
Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med (2008) 1.69
Frequency, prevention, outcome and treatment of ventilator-associated tracheobronchitis: systematic review and meta-analysis. Respir Med (2010) 1.67
Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol (2005) 1.60
Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials. CMAJ (2008) 1.60
Worldwide prevalence of head lice. Emerg Infect Dis (2008) 1.58
Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care (2005) 1.58
Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother (2008) 1.56
Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother (2011) 1.55
Impact of patient position on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials. J Crit Care (2009) 1.55
Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials. Chest (2007) 1.55
Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care (2011) 1.54
Research contribution of different world regions in the top 50 biomedical journals (1995-2002). FASEB J (2006) 1.54
Prevalence of hepatitis B, hepatitis C, and HIV infections among patients in a psychiatric hospital in Greece. Psychiatr Serv (2009) 1.54
Attributable mortality of Acinetobacter baumannii infection among critically ill patients. Clin Infect Dis (2006) 1.52
Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ (2008) 1.51
Impact of passive humidification on clinical outcomes of mechanically ventilated patients: a meta-analysis of randomized controlled trials. Crit Care Med (2007) 1.50
Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J (2007) 1.49
Bowel cleansing before bowel surgery: major discordance between evidence and practice. J Gastrointest Surg (2008) 1.45
Do we still need the aminoglycosides? Int J Antimicrob Agents (2008) 1.45
Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. Ann Surg Oncol (2012) 1.44
World databases of summaries of articles in the biomedical fields. Arch Intern Med (2007) 1.43
Fluoroquinolones versus beta-lactam based regimens for the treatment of osteomyelitis: a meta-analysis of randomized controlled trials. Spine (Phila Pa 1976) (2008) 1.40
Non-physicians may reach correct diagnoses by using Google: a pilot study. Swiss Med Wkly (2008) 1.40
Worldwide trends in quantity and quality of published articles in the field of infectious diseases. BMC Infect Dis (2005) 1.39
From conference abstract to full paper: differences between data presented in conferences and journals. FASEB J (2005) 1.39
Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother (2009) 1.38
Pain and a purple lesion. Am J Med (2006) 1.38
Tuberculosis of the oral cavity: a systematic review. Eur J Oral Sci (2010) 1.37
The impact of article length on the number of future citations: a bibliometric analysis of general medicine journals. PLoS One (2013) 1.35
Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents (2009) 1.35
Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther (2007) 1.34
Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin. Scand J Infect Dis (2005) 1.33
Age distribution of cases of 2009 (H1N1) pandemic influenza in comparison with seasonal influenza. PLoS One (2011) 1.33
Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents (2012) 1.32
Human infections associated with wild birds. J Infect (2007) 1.29
A bibliometric analysis in the fields of preventive medicine, occupational and environmental medicine, epidemiology, and public health. BMC Public Health (2006) 1.27
Mapping health literacy research in the European Union: a bibliometric analysis. PLoS One (2008) 1.25
Infections related to airway stenting: a systematic review. Respiration (2009) 1.21
Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother (2007) 1.21
Serum procalcitonin as a diagnostic marker for neonatal sepsis: a systematic review and meta-analysis. Intensive Care Med (2011) 1.20
Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. Mayo Clin Proc (2005) 1.20
Probiotics for the prevention of respiratory tract infections: a systematic review. Int J Antimicrob Agents (2009) 1.19
Probiotics for the treatment of allergic rhinitis and asthma: systematic review of randomized controlled trials. Ann Allergy Asthma Immunol (2008) 1.18
Treatment of Acinetobacter infections. Expert Opin Pharmacother (2010) 1.18
Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med (2007) 1.17
Frequency, characteristics, and predictors of microbiologically documented nosocomial infections after cardiac surgery. Eur J Cardiothorac Surg (2006) 1.17
Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J Clin Virol (2010) 1.14
Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence. Int J Antimicrob Agents (2008) 1.13
Outcomes after medical and surgical treatment of diverticulitis: a systematic review of the available evidence. J Gastroenterol Hepatol (2007) 1.12
Do psychological variables affect early surgical recovery? PLoS One (2011) 1.11
Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome. PLoS One (2012) 1.10
Incidence of postoperative infections in patients undergoing coronary artery bypass grafting surgery receiving antimicrobial prophylaxis with original and generic cefuroxime. J Infect (2007) 1.09
Health literacy research in Europe: a snapshot. Eur J Public Health (2005) 1.08
Insights into infectious disease in the era of Hippocrates. Int J Infect Dis (2008) 1.07
Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options. Curr Opin Investig Drugs (2008) 1.07
World Wide Web resources on control of nosocomial infections. Crit Care (2007) 1.07
Meta-analyses on behavioral interventions to reduce the risk of transmission of HIV. Infect Dis Clin North Am (2009) 1.07
Colistin and polymyxin B in critical care. Crit Care Clin (2008) 1.06
Free internal medicine case-based education through the World Wide Web: how, where, and with what? Mayo Clin Proc (2007) 1.06
Temporal trends in the impact factor of European versus USA biomedical journals. PLoS One (2011) 1.06
Polymyxins: a review of the current status including recent developments. Ann Acad Med Singapore (2008) 1.06
Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis. Int J Infect Dis (2012) 1.05
Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria. Eur J Clin Pharmacol (2010) 1.05
Cure of post-traumatic recurrent multiresistant Gram-negative rod meningitis with intraventricular colistin. J Infect (2005) 1.05
Risk factors for mesh-related infections after hernia repair surgery: a meta-analysis of cohort studies. World J Surg (2011) 1.05
Clinical assessment and medical treatment of spine infections. Clin Orthop Relat Res (2006) 1.04
World Wide Web hepatitis B virus resources. J Clin Virol (2006) 1.04
Outcome of critically ill oldest-old patients (aged 90 and older) admitted to the intensive care unit. J Am Geriatr Soc (2006) 1.04
Use of international units when dosing colistin will help decrease confusion related to various formulations of the drug around the world. Antimicrob Agents Chemother (2006) 1.03
Reaction to the threat of influenza pandemic: the mass media and the public. Crit Care (2006) 1.03
Chronic bacterial and parasitic infections and cancer: a review. J Infect Dev Ctries (2010) 1.03
Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials. Crit Care Med (2006) 1.03
Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother (2008) 1.03